Is Danaher Still a Recession Resistant Stock?
In the latest indication of how the COVID-19 pandemic is negatively affecting businesses, Danaher (NYSE: DHR) came out recently and withdrew its full-year guidance.
The medically focused company is often seen as being a defensive option for investors, so the update may have come as somewhat of a surprise. Does it change the investment proposition for the stock? Here's the lowdown.
To start, let's take a look at why Danaher is seen as a defensive option. It reports out of three business segments: life sciences, diagnostics, and environmental and applied solutions.
Source Fool.com
